

Clinical Trial Protocol

Iranian Registry of Clinical Trials

13 Jun 2026

The Effect of Spironolactone as Monotherapy on Systolic and Diastolic Blood Pressure in Patients with Essential Hypertension

Protocol summary

Summary

This study has been designed to assess the effect of spironolactone as monotherapy on systolic and diastolic blood pressure in patients suffering from essential hypertension referred to the Health Heart House. In this randomized controlled clinical study, 40 people who are referred to Shiraz Heart House and suffer from essential hypertension according to ambulatory blood pressure holter monitoring have been selected. Inclusion criteria are: systolic blood pressure more than 135 mmhg or diastolic blood pressure more than 85 mmhg. Exclusion criteria are: serum creatinine more than 2 mg/dl; serum potassium more than 5 meq/l; renal or other endocrine diseases and diabetes. These persons have randomly been divided into experiment group (20 persons) receiving Spironolactone and control group (20 persons) who receive placebo. The experiment group has been given one tablet of Spironolactone daily for one month and the control group has been given one tablet of placebo daily for one month. Also low salt and low fat diet will recommend to all patients. At the end, ambulatory blood pressure holter monitoring will be done again. Finally systolic and diastolic blood pressure before and after intervention will be compared with each other.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT201502011525N6**

Registration date: **2015-03-14, 1393/12/23**

Registration timing: **registered_while_recruiting**

Last update:

Update count: **0**

Registration date

2015-03-14, 1393/12/23

Registrant information

Name

Mohammad Javad Zibaeenezhad

Name of organization / entity

Cardiovascular Research Center, Shiraz University of Medical Science

Country

Iran (Islamic Republic of)

Phone

+98 71 1234 3529

Email address

zibaeem2@sums.ac.ir

Recruitment status

Recruitment complete

Funding source

Shiraz University of Medical Sciences

Expected recruitment start date

2014-12-22, 1393/10/01

Expected recruitment end date

2015-05-22, 1394/03/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

The Effect of Spironolactone as Monotherapy on Systolic and Diastolic Blood Pressure in Patients with Essential Hypertension

Public title

The Effect of Spironolactone in Treatment of Essential Hypertension

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria: systolic blood pressure more than 135 mmhg; diastolic blood pressure more than 85 mmhg

Exclusion criteria: serum creatinine more than 2 mg/dl; serum potassium more than 5 meq/l; renal or other endocrine diseases; diabetes

Age

No age limit

Gender

Both

Phase

2-3

Groups that have been masked

No information

Sample size

Target sample size: 40

Randomization (investigator's opinion)

Randomized

Randomization description

Blinding (investigator's opinion)

Double blinded

Blinding description

Placebo

Used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Shiraz University of Medical Sciences

Street address

Shiraz University of Medical Sciences, Zand St, Shiraz

City

Shiraz

Postal code

7134814336

Approval date

2014-12-14, 1393/09/23

Ethics committee reference number

CP-P-9354-5874

Health conditions studied

1

Description of health condition studied

Hypertension

ICD-10 code

I10

ICD-10 code description

Essential (primary) hypertension

Primary outcomes

1

Description

Systolic blood pressure

Timepoint

Before intervention and 1 month after intervention

Method of measurement

Ambulatory 24 hour blood pressure holter monitoring

2

Description

Diastolic blood pressure

Timepoint

Before intervention and 1 month after intervention

Method of measurement

Ambulatory 24 hour blood pressure holter monitoring

Secondary outcomes

1

Description

Level of serum potassium

Timepoint

Before Intervention and One Month After Intervention

Method of measurement

Biochemical Measurements on Blood Sample

Intervention groups

1

Description

Intervention group: Spironolactone, 25 mg oral tablet, one tablet daily for one month

Category

Treatment - Drugs

2

Description

Control group: placebo, oral tablet, one tablet daily for one month

Category

Placebo

Recruitment centers

1

Recruitment center

Name of recruitment center

Cardiovascular Research Center of Shiraz University of Medical Sciences

Full name of responsible person

Amirabbas Sadeghi (resident of cardiology)

Street address

Cardiovascular Research Center, Khalili St, Shiraz

City

Shiraz

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Shiraz University of Medical Sciences

Full name of responsible person

Mrs. Hoghooghi

Street address

Cardiovascular Research center, Khalili St, Shiraz

City

Shiraz

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Shiraz University of Medical Sciences

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

empty

Person responsible for general inquiries

Contact

Name of organization / entity

Shiraz University of Medical Sciences

Full name of responsible person

Amirabbas Sadeghi

Position

Resident of Cardiology

Other areas of specialty/work

Street address

Shiraz University of Medical Sciences, Zand St, Shiraz

City

Shiraz

Postal code

7134814336

Phone

+98 71 3233 2366

Fax

Email

Amirabbasadeghi@yahoo.com

Web page address

Person responsible for scientific inquiries

Contact

Name of organization / entity

Cardiovascular Research Center of Shiraz

Full name of responsible person

Dr. Kamran Aghasadeghi

Position

Internist Cardiologist

Other areas of specialty/work

Street address

Cardiovascular Research Center, Khalili St, Shiraz

City

Shiraz

Postal code

Phone

+98 71 3628 1547

Fax

Email

Aghasadek@sums.ac.ir

Web page address

Person responsible for updating data

Contact

Name of organization / entity

Shiraz University of Medical Sciences

Full name of responsible person

Amirabbas Sadeghi

Position

Resident of Cardiology

Other areas of specialty/work

Street address

Shiraz University of Medical Sciences, Zand St, Shiraz

City

Shiraz

Postal code

Phone

Fax

Email

Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty